2021 | Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma | NEW ENGLAND JOURNAL OF MEDICINE |
2022 | Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma | NEW ENGLAND JOURNAL OF MEDICINE |
2018 | Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
2017 | Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
| NEW ENGLAND JOURNAL OF MEDICINE |
2018 | Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEW ENGLAND JOURNAL OF MEDICINE |
2020 | Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEW ENGLAND JOURNAL OF MEDICINE |
2012 | Porcelain aorta | NEW ENGLAND JOURNAL OF MEDICINE |
2024 | Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
2013 | Riociguat for Pulmonary Hypertension
| NEW ENGLAND JOURNAL OF MEDICINE |
2019 | Rivaroxaban in Patients With Heart Failure | NEW ENGLAND JOURNAL OF MEDICINE |
2023 | Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer
| NEW ENGLAND JOURNAL OF MEDICINE |
2008 | Stents versus coronary-artery bypass grafting for left main coronary artery disease
| NEW ENGLAND JOURNAL OF MEDICINE |
2023 | Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
2020 | Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations | NEW ENGLAND JOURNAL OF MEDICINE |
2007 | The Failing Heart | NEW ENGLAND JOURNAL OF MEDICINE |
2022 | Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
2020 | Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
| NEW ENGLAND JOURNAL OF MEDICINE |
2020 | Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
2022 | Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
2015 | Trial of everolimus-eluting stents or bypass surgery for coronary disease | NEW ENGLAND JOURNAL OF MEDICINE |
2009 | Uric acid and cardiovascular risk. | NEW ENGLAND JOURNAL OF MEDICINE |